A Phase 1 Open-Label Study of the Safety of Intravenous Allogeneic Neonatal Mesenchymal Cells (nMSCs) in Young Adult (1A) and Pediatric (1B) Patients With Dilated Cardiomyopathy (DCM)
NCT06464588
This study is recruiting at 5 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This is a Phase 1 study to determine the safety and efficacy of allogeneic neonatal mesenchymal stromal cells (nMSCs) for the treatment of Dilated Cardiomyopathy. The purpose of the study is to help doctors and scientists learn if allogeneic neonatal mesenchymal stromal cells (nMSCs) infusions are a safe and effective way to improve cardiac function and left ventricular ejection fraction.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Dilated Cardiomyopathy
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 4 to 40 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Emory University
- Last updated on ClinicalTrials.gov
- June 26, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Georgia · 5
- Arthur M. Blank Hospital · Atlanta, GA
- Emory University Hospital · Atlanta, GA
- Grady Memorial Hospital · Atlanta, GA
- Hughes Spalding Children's Hospital · Atlanta, GA
- Scottish Rite Children's Hospital · Atlanta, GA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.